Artivion to Participate in the UBS 2022 Global Healthcare Conference
05/16/2022 - 08:25 AM
ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS 2022 Global Healthcare Conference on Monday, May 23, 2022 at the Lotte New York Palace. The Company's fireside chat is scheduled to begin at 2:45 p.m. ET .
A live webcast of the fireside chat will be accessible through Artivion's website, www.artivion.com , on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
About Artivion, Inc. Headquartered in suburban Atlanta, Georgia , Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com .
Contacts:
Artivion
D. Ashley Lee
Executive Vice President &
Chief Financial Officer
Phone: 770-419-3355
Gilmartin Group LLC
Brian Johnston / Lynn Lewis
Phone: 332-895-3222
investors@artivion.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-to-participate-in-the-ubs-2022-global-healthcare-conference-301547491.html
SOURCE Artivion, Inc.
AORT Rankings
#1241 Ranked by Stock Gains
AORT Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Country
US
City
Kennesaw
About AORT
cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica